A NOVEL VACCINE AGAINST HEAMOPHILUS PARASUIS
The invention pertains to a protein having at least 69% sequence identity with the protein according to SEQ ID No: 1 or an immunogenic fragment of this protein, for use in a prophylactic method to protect a pig against an infection with Haemophilus parasuis serotype 4 and an infection with Haemophilus parasuis serotype 5, by administering a vaccine to the pig, the vaccine comprising the protein or the immunogenic fragment thereof as an antigen. The invention also pertains to a vaccine, a method to manufacture such a vaccine and a method to protect a pig against H. parasuis.
1 . (canceled)
2 . The method of claim 9 , wherein the protein antigen comprises an amino acid sequence that has at least 90% sequence identity with according to SEQ ID No: NO: 1, or an immunogenic fragment thereof
3 . The method of claim 2 , wherein the protein antigen comprises an amino acid sequence that has at least 95% sequence identity with SEQ ID NO: 1, or an immunogenic fragment thereof.
4 . The method of claim 3 , wherein the protein antigen comprises the amino acid sequence of SEQ ID NO: 1, or an immunogenic fragment thereof.
5 . The method of claim 9 , wherein said administering of the vaccine protects the pig against an increased risk of mortality due to the infection with Haemophilus parasuis serotype 4 and/or serotype 5.
6 . The method of claim 9 , wherein said administering of the vaccine protects the pig against one or more clinical signs due to the infection with Haemophilus parasuis serotype 4 and/or serotype 5.
7 . A vaccine to protect a pig against an infection with Haemophilus parasuis serotype 4 and an infection with Haemophilus parasuis serotype 5, comprising a protein antigen comprising an amino acid sequence that has at least 69% sequence identity with SEQ ID NO: 1, or an immunogenic fragment thereof of this protein, and a pharmaceutically acceptable carrier.
8 . (canceled)
9 . A method to protect a pig against an infection with Haemophilus parasuis serotype 4 and an infection with Haemophilus parasuis serotype 5 by comprising administering a vaccine to the pig, wherein the vaccine comprises a protein antigen that comprises an amino acid sequence that has at least 69% sequence identity with SEQ ID NO: 1, or an immunogenic fragment thereof of this protcin.
10 . The vaccine to protect a pig against an infection with Haemophilus parasuis serotype 4 and an infection with Haemophilus parasuis serotype 5 of claim 7 , wherein the protein antigen comprises an amino acid sequence that has at least 90% sequence identity with SEQ ID NO: 1, or an immunogenic fragment thereof and a pharmaceutically acceptable carrier.
11 . The vaccine to protect a pig against an infection with Haemophilus parasuis serotype 4 and an infection with Haemophilus parasuis serotype 5 of claim 10 , wherein the protein antigen comprises an amino acid sequence that has at least 95% sequence identity with SEQ ID NO: 1, or an immunogenic fragment thereof and a pharmaceutically acceptable carrier.
12 . The vaccine to protect a pig against an infection with Haemophilus parasuis serotype 4 and an infection with Haemophilus parasuis serotype 5 of claim 7 , wherein the protein antigen comprises the amino acid sequence of SEQ ID NO: 1, or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.